N@N

VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 6, 2010) - Global Health Ventures Inc. (OTCBB:GHLV) (the "Company"), a specialty pharmaceutical company today announced that a large number of drugs and chemicals can be delivered rapidly to the blood using its proprietary sublingual technology. Studies carried out with physiochemical properties of several blockbuster drugs, showed that if they are put into our formulation they can be delivered to the blood rapidly through sublingual route. While certain therapeutic drugs are already delivered sublingually such as nitroglycerine, many other drugs (more then 90%) do not pass through oral mucosa. By reformulating these drugs with permeating enhancers and taste masking chemicals, many drugs can be delivered rapidly to the blood via sublingual route.

"We will continue evaluating the effectiveness of our formulation to many blockbuster drugs upon their loss of patent protection. This process will not only result in market advantage such as faster onset of action, increased bioavailability, lower dosage, and fewer side effects, but can reposition the drugs for another 15-20 years with patent exclusivity that can help our partners hold significant portion of their revenue. This opportunity would otherwise be lost due to availability of generics," said Dr. Hassan Salari, President and CEO.

ABOUT GLOBAL HEALTH VENTURES - Global Health Ventures is a specialty pharma focused on the life style products. The company has a new proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastro-intestinal system, a process that can greatly reduce side effects associated with the drug. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach blood stream rapidly, producing maximal effect and having less of the unwanted side effects which are associated with the standard oral administration route drugs. The Company also uses the same technology to deliver a vast number of other FDA approved drugs where they are needed to act rapidly. These include, stress relief, sleeping disorders, pain killers, anti-allergy, heart medication and addiction replacement.

Notice Regarding Forward Looking Statements - This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.